Federal grants to Avm Biotechnology, Inc.
Avm Biotechnology, Inc. in Seattle, Washington received $5.0 million in federal grants from fiscal 2021 to 2025, across 4 awards. Its largest program was Cancer Treatment Research, with $3.4 million. In fiscal 2025 it was awarded $992,425.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$5.0 million
- Awards4
- Awarded in FY 2025$992,425
- Largest award$2.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 0 | $0 |
| FY 2022 | 3 | $2.1 million |
| FY 2023 | 2 | $2.0 million |
| FY 2024 | 0 | $0 |
| FY 2025 | 1 | $992,425 |
Programs that fund Avm Biotechnology, Inc.
| Program | Awards | Amount |
|---|---|---|
| Cancer Treatment Research | 3 | $3.4 million |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 1 | $1.6 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 4 | $5.0 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Expedited expansion cohort clinical trial for relapsed/refractory 'no-option' non-hodgkin's lymphoma/leukemia patients - abstract non-hodgkin’s lymphoma (NHL) is the 7th most common cancer in the U.S., with over half of the 77,240 people diagnosed annually over age 65. In about 50% of cases, disease | Cancer Treatment Research | June 10, 2022 | $2.0 million |
| Targeted lymphoablation as an alternative to hsct to cure T1D - project summary with insulin being the only approved treatment of type 1 diabetes (T1D), there is a very large unmet medical need for a definitive cure for pediatric and adult patients. In the U.S., diabetes currently affects 14% of the | Diabetes, Digestive, and Kidney Diseases Extramural Research | March 30, 2022 | $1.6 million |
| Immunomodulatory AVM0703 to bridge relapsed/refractory diffuse large b-cell lymphoma patients to car-t cell immunotherapy - project summary the approval of various chimeric antigen receptor-t cells (car-t cells) for second- or third-line therapy has greatly expanded the treatment options available t | Cancer Treatment Research | September 8, 2025 | $992,425 |
| AVM0703 combined with non-hodgkin's lymphoma standard of care to enhance complete response rates without additional toxicities - project summary non-hodgkin’s lymphoma (NHL) represents 4% of all cancer diagnosed in the U.S., and as many as 50% of patients will relapse within 2 years of diagnosis and | Cancer Treatment Research | August 5, 2022 | $399,193 |
Questions people ask
How much federal grant money does Avm Biotechnology, Inc. get?
$5.0 million in 4 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Avm Biotechnology, Inc. the most?
The Department of Health and Human Services, with $5.0 million in 4 awards.
What is Avm Biotechnology, Inc.'s largest federal grant?
$2.0 million under Cancer Treatment Research, with its first action in the period on June 10, 2022. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Avm Biotechnology, Inc.?
Its largest are Cancer Treatment Research and Diabetes, Digestive, and Kidney Diseases Extramural Research.
Other grant recipients in Seattle
- University of Washington
- Central Puget Sound Regional Transit Authority
- Fred Hutchinson Cancer Center
- King County Metro Transit
- Port of Seattle
- Seattle Children's Hospital
- Allen Institute
- Seattle Housing Authority
Largest federal grant recipients in Washington · Federal grants in Washington